| Heart disease and stroke statistics—2017 update: a report from the American Heart Association EJ Benjamin, MJ Blaha, SE Chiuve, M Cushman, SR Das, R Deo, ... circulation 135 (10), e146-e603, 2017 | 51919* | 2017 |
| Angiotensin–neprilysin inhibition versus enalapril in heart failure JJV McMurray, M Packer, AS Desai, J Gong, MP Lefkowitz, AR Rizkala, ... New England Journal of Medicine 371 (11), 993-1004, 2014 | 7639 | 2014 |
| Dapagliflozin in patients with heart failure and reduced ejection fraction JJV McMurray, SD Solomon, SE Inzucchi, L Køber, MN Kosiborod, ... New England Journal of Medicine 381 (21), 1995-2008, 2019 | 6906 | 2019 |
| Spironolactone for heart failure with preserved ejection fraction B Pitt, MA Pfeffer, SF Assmann, R Boineau, IS Anand, B Claggett, ... New England Journal of Medicine 370 (15), 1383-1392, 2014 | 2917 | 2014 |
| Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction SD Solomon, JJV McMurray, IS Anand, J Ge, CSP Lam, AP Maggioni, ... New England Journal of Medicine 381 (17), 1609-1620, 2019 | 2331 | 2019 |
| Strategies for multivessel revascularization in patients with diabetes ME Farkouh, M Domanski, LA Sleeper, FS Siami, G Dangas, M Mack, ... New England journal of medicine 367 (25), 2375-2384, 2012 | 2255 | 2012 |
| Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction SD Solomon, JJV McMurray, B Claggett, RA de Boer, D DeMets, ... New England Journal of Medicine 387 (12), 1089-1098, 2022 | 2048 | 2022 |
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ... New England Journal of Medicine 367 (23), 2204-2213, 2012 | 1703 | 2012 |
| Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial MA Pfeffer, B Claggett, SF Assmann, R Boineau, IS Anand, N Clausell, ... Circulation 131 (1), 34-42, 2015 | 1066 | 2015 |
| Rehospitalization for heart failure: predict or prevent? AS Desai, LW Stevenson Circulation 126 (4), 501-506, 2012 | 833 | 2012 |
| Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure M Packer, JJV McMurray, AS Desai, J Gong, MP Lefkowitz, AR Rizkala, ... Circulation 131 (1), 54-61, 2015 | 830 | 2015 |
| SGLT2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials M Vaduganathan, KF Docherty, BL Claggett, PS Jhund, RA de Boer, ... The Lancet 400 (10354), 757-767, 2022 | 730 | 2022 |
| 2017 cardiovascular and stroke endpoint definitions for clinical trials KA Hicks, KW Mahaffey, R Mehran, SE Nissen, SD Wiviott, B Dunn, ... Journal of the American College of Cardiology 71 (9), 1021-1034, 2018 | 727 | 2018 |
| Treatment of anemia with darbepoetin alfa in systolic heart failure K Swedberg, JB Young, IS Anand, S Cheng, AS Desai, R Diaz, ... New England Journal of Medicine 368 (13), 1210-1219, 2013 | 713 | 2013 |
| Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not … SM Dunlay, MM Givertz, D Aguilar, LA Allen, M Chan, AS Desai, A Deswal, ... Circulation 140 (7), e294-e324, 2019 | 676 | 2019 |
| Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus ET Kato, MG Silverman, O Mosenzon, TA Zelniker, A Cahn, RHM Furtado, ... Circulation 139 (22), 2528-2536, 2019 | 667 | 2019 |
| Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction SD Solomon, B Claggett, EF Lewis, A Desai, I Anand, NK Sweitzer, ... European heart journal 37 (5), 455-462, 2016 | 603 | 2016 |
| Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction VR Taqueti, SD Solomon, AM Shah, AS Desai, JD Groarke, MT Osborne, ... European heart journal 39 (10), 840-849, 2018 | 571 | 2018 |
| Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials AS Desai, JC Fang, WH Maisel, KL Baughman Jama 292 (23), 2874-2879, 2004 | 566 | 2004 |
| Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for … JJV McMurray, M Packer, AS Desai, J Gong, MP Lefkowitz, AR Rizkala, ... European journal of heart failure 15 (9), 1062-1073, 2013 | 559 | 2013 |
